NeuroPace, Inc.
NPCEHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NeuroPace, Inc. focuses on Medical Devices services and products. NeuroPace, Inc. operates as a medical device company in the United States. With a market capitalization of $506.6M, it sits in small-cap territory. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
Market Cap
$506.6M
Beta
1.95
P/E (TTM)
—
P/E (Fwd)
-66.43
EPS (TTM)
$-0.47
EPS (Fwd)
$-0.22
ROE
-103.3%
ROA
-7.5%
Cash
$51.7M
Total Debt
$69.9M
Free CF
-$2.6M
52W Change
54.1%
Annual Financials
Cash vs Debt
Where NPCE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NPCE finished 0.65% below its 150-day moving average ($15.29) and 1.75% below its 200-day moving average ($15.46). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NPCE overbought or oversold?
At the September 3, 2026 close, NPCE's RSI(14) was 58.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $51.7M in cash, though total debt stands at $69.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$2.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -103.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $45.5M (2022) to $100.0M (2025), reflecting a 120% increase over the period.
A beta of 1.95 means NPCE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NeuroPace, Inc.'s trajectory.